MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
MIRA Pharmaceuticals (NASDAQ:MIRA) announced positive preclinical results for Mira-55, its proprietary non-psychotropic marijuana analog, which demonstrated morphine-comparable pain relief in inflammatory pain models without causing inflammation. The drug, engineered to selectively activate CB2 cannabinoid receptors, reduced pain sensitivity by approximately threefold while avoiding euphoria and sedation risks.
Key developments include the DEA's determination that Mira-55 is not classified as a controlled substance, enhancing its clinical and commercial potential. Additionally, MIRA reported progress on its merger with SKNY Pharmaceuticals, whose SKNY-1 therapy showed 30% body weight reduction and nicotine craving reversal in recent studies. The SEC completed its merger proxy review without comments.
[ "Mira-55 demonstrated morphine-equivalent pain relief without addiction or sedation risks", "DEA determined Mira-55 is not a controlled substance, removing development barriers", "SKNY-1 acquisition target showed 30% body weight reduction in studies", "SEC completed merger proxy review with no comments, accelerating SKNY acquisition", "Company advancing two complementary non-opioid pain treatments (Mira-55 and Ketamir-2)" ]MIRA Pharmaceuticals (NASDAQ:MIRA) ha annunciato risultati preclinici positivi per Mira-55, il suo analogo proprietario della marijuana non psicotropo, che ha dimostrato un sollievo dal dolore comparabile alla morfina nei modelli di dolore infiammatorio senza causare infiammazione. Il farmaco, progettato per attivare selettivamente i recettori cannabinoidi CB2, ha ridotto la sensibilità al dolore di circa tre volte evitando i rischi di euforia e sedazione.
I principali sviluppi includono la determinazione della DEA che Mira-55 non è classificato come sostanza controllata, aumentando il suo potenziale clinico e commerciale. Inoltre, MIRA ha riportato progressi nella fusione con SKNY Pharmaceuticals, la cui terapia SKNY-1 ha mostrato una riduzione del peso corporeo del 30% e un'inversione del desiderio di nicotina in studi recenti. La SEC ha completato la revisione del proxy per la fusione senza commenti.
- Mira-55 ha dimostrato un sollievo dal dolore equivalente alla morfina senza rischi di dipendenza o sedazione
- La DEA ha stabilito che Mira-55 non è una sostanza controllata, rimuovendo ostacoli allo sviluppo
- L'obiettivo di acquisizione SKNY-1 ha mostrato una riduzione del 30% del peso corporeo negli studi
- La SEC ha completato la revisione del proxy per la fusione senza commenti, accelerando l'acquisizione di SKNY
- L'azienda sta avanzando con due trattamenti complementari non oppioidi per il dolore (Mira-55 e Ketamir-2)
MIRA Pharmaceuticals (NASDAQ:MIRA) anunció resultados preclÃnicos positivos para Mira-55, su análogo propietario de marihuana no psicotrópico, que demostró alivio del dolor comparable a la morfina en modelos de dolor inflamatorio sin causar inflamación. El medicamento, diseñado para activar selectivamente los receptores cannabinoides CB2, redujo la sensibilidad al dolor en aproximadamente tres veces evitando riesgos de euforia y sedación.
Los desarrollos clave incluyen la determinación de la DEA de que Mira-55 no está clasificado como sustancia controlada, lo que mejora su potencial clÃnico y comercial. Además, MIRA reportó avances en su fusión con SKNY Pharmaceuticals, cuya terapia SKNY-1 mostró una reducción del 30% del peso corporal y reversión del deseo de nicotina en estudios recientes. La SEC completó su revisión del proxy de fusión sin comentarios.
- Mira-55 demostró alivio del dolor equivalente a la morfina sin riesgos de adicción o sedación
- La DEA determinó que Mira-55 no es una sustancia controlada, eliminando barreras de desarrollo
- El objetivo de adquisición SKNY-1 mostró una reducción del 30% del peso corporal en estudios
- La SEC completó la revisión del proxy de fusión sin comentarios, acelerando la adquisición de SKNY
- La compañÃa avanza con dos tratamientos complementarios para el dolor no opioides (Mira-55 y Ketamir-2)
MIRA Pharmaceuticals (NASDAQ:MIRA)ëŠ� ë¹„ì •ì‹ í™œì„� 대ë§� ìœ ì‚¬ì²´ì¸ Mira-55ì—� 대í•� ê¸ì •ì ì¸ ì „ìž„ìƒ� ê²°ê³¼ë¥� 발표했습니다. Mira-55ëŠ� ì—¼ì¦ì„� í†µì¦ ëª¨ë¸ì—서 모르핀ê³� ìœ ì‚¬í•� í†µì¦ ì™„í™”ë¥� 보였으며 ì—¼ì¦ì� ìœ ë°œí•˜ì§€ 않았습니ë‹�. ì� ì•½ë¬¼ì€ ì„ íƒì 으ë¡� CB2 칸나비노ì´ë“œ 수용체를 활성화하ë„ë¡ ì„¤ê³„ë˜ì–´ ì•� 3ë°� í†µì¦ ë¯¼ê°ë„를 ê°ì†Œì‹œí‚¤ë©´ì„œë� 행복ê°ê³¼ ì§„ì • 위험ì� 피했습니ë‹�.
주요 ë°œì „ 사í•으로ëŠ� Mira-55ê°€ í†µì œ 물질ë¡� 분류ë˜ì§€ 않는다는 DEAì� ê²°ì •ì� 있어 ìž„ìƒ ë°� ìƒì—…ì � ìž ìž¬ë ¥ì´ í–¥ìƒë˜ì—ˆìŠµë‹ˆë‹�. ë˜í•œ MIRAëŠ� SKNY Pharmaceuticals와ì� 합병 ì§„í–‰ ìƒí™©ì� ë³´ê³ í–ˆìœ¼ë©�, SKNY-1 ì¹˜ë£Œì œëŠ” 최근 연구ì—서 체중 30% ê°ì†Œì™€ 니코í‹� ê°ˆë§ ë°˜ì „ì� 보였습니ë‹�. SECëŠ� 합병 ëŒ€ë¦¬ì¸ ê²€í† ë¥¼ 무사íž� 완료했습니다.
- Mira-55ëŠ� 중ë…ì´ë‚˜ ì§„ì • 위험 ì—†ì´ ëª¨ë¥´í•€ê³� ë™ë“±í•� í†µì¦ ì™„í™”ë¥� ìž…ì¦
- DEAëŠ� Mira-55ë¥� í†µì œ 물질ë¡� 분류하지 않아 개발 장벽 ì œê±°
- SKNY-1 ì¸ìˆ˜ 대ìƒì€ 연구ì—서 체중 30% ê°ì†Œë¥� ë³´ìž„
- SECëŠ� 합병 ëŒ€ë¦¬ì¸ ê²€í† ë¥¼ 무사íž� 완료하여 SKNY ì¸ìˆ˜ ê°€ì†í™”
- 회사ëŠ� ë‘� 가지 ìƒí˜¸ 보완ì ì¸ ë¹„ì˜¤í”¼ì˜¤ì´ë“œ í†µì¦ ì¹˜ë£Œì �(Mira-55 ë°� Ketamir-2)ë¥� 개발 ì¤�
MIRA Pharmaceuticals (NASDAQ:MIRA) a annoncé des résultats précliniques positifs pour Mira-55, son analogue propriétaire du cannabis non psychotrope, qui a démontré un soulagement de la douleur comparable à celui de la morphine dans des modèles de douleur inflammatoire sans provoquer d'inflammation. Le médicament, conçu pour activer sélectivement les récepteurs cannabinoïdes CB2, a réduit la sensibilité à la douleur d'environ trois fois tout en évitant les risques d'euphorie et de sédation.
Les développements clés incluent la détermination de la DEA que Mira-55 n'est pas classé comme substance contrôlée, augmentant ainsi son potentiel clinique et commercial. De plus, MIRA a rapporté des progrès dans sa fusion avec SKNY Pharmaceuticals, dont la thérapie SKNY-1 a montré une réduction de 30 % du poids corporel et une inversion du craving de nicotine dans des études récentes. La SEC a terminé son examen du proxy de fusion sans commentaires.
- Mira-55 a démontré un soulagement de la douleur équivalent à la morphine sans risques d’addiction ou de sédation
- La DEA a déterminé que Mira-55 n’est pas une substance contrôlée, supprimant ainsi les obstacles au développement
- La cible d’acquisition SKNY-1 a montré une réduction de 30 % du poids corporel dans les études
- La SEC a terminé l’examen du proxy de fusion sans commentaires, accélérant l’acquisition de SKNY
- L’entreprise fait progresser deux traitements complémentaires de la douleur non opioïdes (Mira-55 et Ketamir-2)
MIRA Pharmaceuticals (NASDAQ:MIRA) gab positive präklinische Ergebnisse für Mira-55 bekannt, ein firmeneigenes nicht-psychotropes Marihuana-Analogon, das in Modellen für entzündliche Schmerzen eine schmerzlindernde Wirkung vergleichbar mit Morphin zeigte, ohne Entzündungen zu verursachen. Das Medikament, das gezielt CB2-Cannabinoidrezeptoren aktiviert, reduzierte die Schmerzempfindlichkeit um etwa das Dreifache und vermied dabei Risiken wie Euphorie und Sedierung.
Wichtige Entwicklungen umfassen die Feststellung der DEA, dass Mira-55 nicht als kontrollierte Substanz eingestuft wird, was das klinische und kommerzielle Potenzial erhöht. Zudem berichtete MIRA über Fortschritte bei der Fusion mit SKNY Pharmaceuticals, deren SKNY-1-Therapie in jüngsten Studien eine 30%ige Gewichtsreduktion und eine Umkehr des Nikotinverlangens zeigte. Die SEC schloss ihre Prüfung des Fusionsproxies ohne Kommentare ab.
- Mira-55 zeigte morphinähnliche Schmerzlinderung ohne Sucht- oder Sedierungsrisiken
- DEA stellte fest, dass Mira-55 keine kontrollierte Substanz ist, was Entwicklungsbarrieren beseitigt
- Das Übernahmeziel SKNY-1 zeigte in Studien eine 30%ige Gewichtsreduktion
- Die SEC schloss die Prüfung des Fusionsproxies ohne Kommentare ab und beschleunigt so die SKNY-Übernahme
- Das Unternehmen entwickelt zwei sich ergänzende nicht-opioide Schmerzbehandlungen (Mira-55 und Ketamir-2)
- None.
- Mira-55 is still in preclinical stage, requiring lengthy development before commercialization
- Clinical trials and regulatory approvals still pending for both lead compounds
Insights
MIRA's Mira-55 shows morphine-level pain relief without opioid risks in preclinical tests, representing significant potential in the lucrative pain market.
MIRA Pharmaceuticals' preclinical results for Mira-55 represent a significant development in the pain management landscape. The compound demonstrated threefold reduction in pain sensitivity in a gold-standard formalin model of inflammatory pain, with efficacy comparable to morphine but without the associated risks of addiction or sedation.
What makes Mira-55 particularly promising is its selective pharmacological profile. The compound is engineered to primarily activate CB2 cannabinoid receptors (associated with pain relief and anti-inflammatory effects) while minimizing activation of CB1 receptors (associated with psychotropic effects). This selectivity explains why Mira-55 doesn't produce the euphoria, sedation, or pro-inflammatory side effects seen with THC.
The DEA's determination that Mira-55 is not a controlled substance removes a significant regulatory hurdle that typically complicates cannabinoid-based drug development. This classification substantially streamlines the potential path to market and enhances commercial viability.
MIRA is building a diversified pain management portfolio with two complementary mechanisms: Mira-55 for inflammatory pain and Ketamir-2 (an NMDA receptor antagonist) for neuropathic pain. This dual approach addresses distinct pain pathways and positions the company to target multiple segments of the $74+ billion global pain management market.
The SEC's completion of its merger proxy review without comments for the SKNY Pharmaceuticals acquisition represents important corporate progress. SKNY-1's dual potential in obesity and nicotine addiction could further diversify MIRA's pipeline with exposure to two additional high-value therapeutic areas.
The next critical milestone will be the IND submission for Mira-55, which will determine when human clinical trials can begin. While these preclinical results are promising, investors should recognize that many compounds show efficacy in animal models but fail in human trials.
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets
MIAMI, FLORIDA / / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation.
Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects.
"These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain."
Study Overview and Key Findings
Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume.
Key findings:
Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline levels.
Its analgesic effect was equivalent to morphine, the standard opioid comparator in the study.
No sedation or inflammatory swelling was observed with Mira-55 treatment.
Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development.
These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile.
"Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards."
Strategic Fit Within MIRA's Pain Portfolio
Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain.
"With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline."
Corporate Update on SKNY Merger
MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a
"We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth."
Next Steps
MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at . MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Helga Moya
[email protected]
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
View the original on ACCESS Newswire